source
- Rezolute’s phase 3 trial of ersodetug meets primary endpoint in tumor hyperinsulinismRezolute reported that its phase 3 Uplift study of ersodetug in tumor hyperinsulinism achieved its primary endpoint. The trial required at least nine of 16 patients to show a 50% or greater reduct…
- Oura to acquire telehealth firm Counsel Health, raising conflict-of-interest concerns for Eli LillyOura, known for its smart rings, announced it will purchase Counsel Health, a telehealth startup that connects patients with clinicians for GLP-1 prescriptions. The acquisition will give Counsel c…